The trial’s first phase will begin in university hospitals across the Netherlands, Denmark, Germany and Sweden.

CTA approval marks Anocca’s transition to a clinical-stage companyFirst-in-human VIDAR-1 trial begins with the deployment of ANOC-001 in Advanced ...

Anocca has achieved regulatory approval for its first clinical trial, VIDAR-1, a major milestone in the company’s transition ...

European regulators have cleared Anocca to begin a Phase I/II umbrella trial of its lead targeted T-cell receptor (TCR) therapy ANOC-001 and other pipeline candidates in certain advanced pancreatic ...

Anocca has submitted its first clinical trial application (CTA) to the European Medicines Agency (EMA) for conducting the Phase I/II VIDAR-1 trial. The trial's commencement depends on the EMA's ...